Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly Lee

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Blood|February 19, 2026
One ball, two hitsHolly Lee
Blood|July 10, 2025
Silence of the myeloma clones: GPRC5D epigenetic regulationHolly Lee, Nizar J Bahlis
Environmental Science & Technology|April 14, 2011
A pilot survey of legacy and current commercial fluorinated chemicals in human sera from United States donors in 2009Holly Lee, Scott A Mabury
Environmental Science & Technology|February 23, 2017
Sorption of Perfluoroalkyl Phosphonates and Perfluoroalkyl Phosphinates in SoilsHolly Lee, Scott A Mabury
Acta Haematologica|February 27, 2020
The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple MyelomaHolly Lee, Victor H Jimenez-Zepeda
Environmental Science & Technology|April 2, 2010
Biodegradation of polyfluoroalkyl phosphates as a source of perfluorinated acids to the environmentHolly Lee, Jessica D'eon, Scott A Mabury
Hematology. American Society of Hematology. Education Program|December 9, 2023
Current use of bispecific antibodies to treat multiple myelomaHolly Lee, Paola Neri, Nizar J Bahlis
Hematology/Oncology Clinics of North America|February 1, 2024
Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and ResistanceHolly Lee, Paola Neri, Nizar J Bahlis
Blood|January 9, 2024
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanismsHolly Lee, Paola Neri, Nizar J Bahlis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Artificial Intelligence Individualized Risk Classifier in Multiple MyelomaPaola Neri, Holly Lee, Nizar J Bahlis
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Blood|February 19, 2026
One ball, two hitsHolly Lee
Blood|July 10, 2025
Silence of the myeloma clones: GPRC5D epigenetic regulationHolly Lee, Nizar J Bahlis
Environmental Science & Technology|April 14, 2011
A pilot survey of legacy and current commercial fluorinated chemicals in human sera from United States donors in 2009Holly Lee, Scott A Mabury
Environmental Science & Technology|February 23, 2017
Sorption of Perfluoroalkyl Phosphonates and Perfluoroalkyl Phosphinates in SoilsHolly Lee, Scott A Mabury
Acta Haematologica|February 27, 2020
The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple MyelomaHolly Lee, Victor H Jimenez-Zepeda
Environmental Science & Technology|April 2, 2010
Biodegradation of polyfluoroalkyl phosphates as a source of perfluorinated acids to the environmentHolly Lee, Jessica D'eon, Scott A Mabury
Hematology. American Society of Hematology. Education Program|December 9, 2023
Current use of bispecific antibodies to treat multiple myelomaHolly Lee, Paola Neri, Nizar J Bahlis
Hematology/Oncology Clinics of North America|February 1, 2024
Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and ResistanceHolly Lee, Paola Neri, Nizar J Bahlis
Blood|January 9, 2024
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanismsHolly Lee, Paola Neri, Nizar J Bahlis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Artificial Intelligence Individualized Risk Classifier in Multiple MyelomaPaola Neri, Holly Lee, Nizar J Bahlis
Pageof 5